178 related articles for article (PubMed ID: 10494510)
41. Induction chemotherapy in head and neck cancer.
Hitt R
Ann Oncol; 2006 Sep; 17 Suppl 10():x42-4. PubMed ID: 17018749
[No Abstract] [Full Text] [Related]
42. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects?
Ang KK
J Clin Oncol; 2004 Dec; 22(23):4657-9. PubMed ID: 15534361
[No Abstract] [Full Text] [Related]
43. The chemotherapy of head and neck cancer.
de Mulder PH
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S33-7. PubMed ID: 10630367
[TBL] [Abstract][Full Text] [Related]
44. [The viewpoint of the radiotherapy oncologist].
Corvò R
Tumori; 2008; 94(4):suppl 30-3. PubMed ID: 18822715
[No Abstract] [Full Text] [Related]
45. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
Abitbol AA; Schwade JG; Lewin AA; Sridhar K; Brandon AH; Markoe AM; Casiano RR; Houdek PV; Serago C; Miller DJ
Am J Clin Oncol; 1992 Jun; 15(3):250-5. PubMed ID: 1590280
[TBL] [Abstract][Full Text] [Related]
46. [Use of docetaxel in treatment of squamous-cell carcinoma of head and neck].
Subramanian S; Kanagavel D; Petenko NN; Orlova KV; Samoĭlenko IV; Demidov LV
Vopr Onkol; 2011; 57(4):421-6. PubMed ID: 22191228
[No Abstract] [Full Text] [Related]
47. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer.
Adelstein DJ
Curr Opin Oncol; 1998 May; 10(3):213-8. PubMed ID: 9619357
[TBL] [Abstract][Full Text] [Related]
48. Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure.
Scher RL; Esclamado RM
Semin Radiat Oncol; 2009 Jan; 19(1):17-23. PubMed ID: 19028341
[TBL] [Abstract][Full Text] [Related]
49. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Haddad R; Tishler RB; Norris CM; Mahadevan A; Busse P; Wirth L; Goguen LA; Sullivan CA; Costello R; Case MA; Posner MR
Oncologist; 2003; 8(1):35-44. PubMed ID: 12604730
[TBL] [Abstract][Full Text] [Related]
50. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Cooper JS; Pajak TF; Forastiere AA; Jacobs J; Campbell BH; Saxman SB; Kish JA; Kim HE; Cmelak AJ; Rotman M; Machtay M; Ensley JF; Chao KS; Schultz CJ; Lee N; Fu KK;
N Engl J Med; 2004 May; 350(19):1937-44. PubMed ID: 15128893
[TBL] [Abstract][Full Text] [Related]
51. Re: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Parsons JT; Mendenhall WM
J Natl Cancer Inst; 1996 Oct; 88(19):1407-8. PubMed ID: 8827019
[No Abstract] [Full Text] [Related]
52. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
[TBL] [Abstract][Full Text] [Related]
53. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?
Chen AM; Farwell DG; Lau DH; Li BQ; Luu Q; Donald PJ
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):346-52. PubMed ID: 20933340
[TBL] [Abstract][Full Text] [Related]
54. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
[TBL] [Abstract][Full Text] [Related]
55. [Role of neoadjuvant chemotherapy for management of resectable head and neck cancer].
Horiuchi M; Tamura Y; Miyake H
Gan To Kagaku Ryoho; 1994 Mar; 21(4):417-24. PubMed ID: 8129381
[TBL] [Abstract][Full Text] [Related]
56. Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer.
Posner MR
Ann Oncol; 2010 Oct; 21 Suppl 7():vii246-51. PubMed ID: 20943623
[TBL] [Abstract][Full Text] [Related]
57. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
58. Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?
Herchenhorn D; Ferreira CG
J Clin Oncol; 2011 Apr; 29(10):e283-4; author reply e285-7. PubMed ID: 21300921
[No Abstract] [Full Text] [Related]
59. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results.
Adelstein DJ; Saxton JP; Lavertu P; Tuason L; Wood BG; Wanamaker JR; Eliachar I; Strome M; Van Kirk MA
Head Neck; 1997 Oct; 19(7):567-75. PubMed ID: 9323144
[TBL] [Abstract][Full Text] [Related]
60. Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer.
Lavertu P; Bonafede JP; Adelstein DJ; Saxton JP; Strome M; Wanamaker JR; Eliachar I; Wood BG
Arch Otolaryngol Head Neck Surg; 1998 Apr; 124(4):401-6. PubMed ID: 9559686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
